Zheng and coworkers have used this methodology of xenotransplantation and have obtained the development of 10 patient-derived NSCLC xenograft models, representative of various genetic abnormalities observed in these tumors, such as EGFR mutations, KRAS mutations, FGFR1 amplifications and MET amplifications [212]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.